首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 處方藥 > 氣喘及慢性阻塞性肺病治療藥物:全球市場(2011∼2021年)
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

氣喘及慢性阻塞性肺病治療藥物:全球市場(2011∼2021年)

Asthma and COPD Therapies: World Market 2011-2021

出版商 Visiongain
出版日期 2011年08月 商品編碼 214196
內容資訊 英文  
價格
US $ 2331 PDF by E-mail (Single User License)
US $ 4663 PDF by E-mail (Departmental License)
US $ 7772 PDF by E-mail (Site License)
US $ 10882 PDF by E-mail (Global Site License)


氣喘及慢性阻塞性肺病治療藥物:全球市場(2011∼2021年) 是由出版商Visiongain在2011年08月所出版的。 這份英文市場調查報告書價格從美金2331起跳。

簡介

本報告提供氣喘及慢性阻塞性肺部疾病的治療藥物市場相關調查分析，2011年趨勢與到2021年為止的收益預測，市場機會，再加上主要企業預測等彙整資料，為您概述為以下內容。

第1章 摘要整理

第2章 氣喘及慢性阻塞性肺病治療藥物的簡介

  • 簡介
    • 氣喘及慢性阻塞性肺病市場
  • 呼吸疾病概要
  • 氣喘
    • 原因和發病
    • 得病率增加
    • 費用急劇上升
    • 氣喘治療
    • 施打方法:吸入
  • 慢性阻塞性肺部疾病
    • 症狀
    • 管理
    • 增加趨勢
    • 經濟負擔
  • 呼吸疾病治療主要的藥物類別
    • 併用藥物
    • 白三烯抑制劑
    • 皮質類固醇
    • β2受體激動劑
    • 抗組織胺藥物
    • 單株抗體

第3章 氣喘·慢性阻塞性肺病治療藥物市場:2011∼2021年

  • 全球市場:2010年
  • 藥物治療的成長市場
    • 銷售額預測:2011∼2015年
    • 腫瘤企業
    • GSK銷售額預測:2011∼2015年
    • GSK銷售額預測:2016∼2021年
    • Merck:2011∼2015年
    • Merck:2016∼2021年
    • Boehringer Ingelheim:2011∼2015年
    • Boehringer Ingelheim:2016∼2021年
    • AstraZeneca:2011∼2015年
    • AstraZeneca:2016∼2021年
    • Novartis:2011∼2015年
    • Novartis:2016∼2021年
    • Nycomed:2011∼2015年
    • Nycomed:2016∼2021年
    • 摘要
  • 主要國家:2011∼2021年
    • 美國
    • 日本
    • 歐洲
    • 新興國家
    • 中國
    • 印度
  • 市場預測摘要

第4章 GlaxoSmithKline的市場貢獻

  • 簡介
  • 腫瘤產品
  • 銷售額預測:2011∼2021年
  • 開發中產品:2011年
  • 摘要

第5章 Merck的市場貢獻

  • 簡介
  • 腫瘤產品
  • 銷售額預測:2011∼2021年
  • 開發中產品:2011年
  • 摘要

第6章 Boehringer Ingelheim的市場貢獻

  • 簡介
  • 腫瘤產品
  • 銷售額預測:2011∼2021年
  • 開發中產品:2011年
  • 摘要

第7章 AstraZeneca的市場貢獻

  • 簡介
  • 腫瘤產品
  • 銷售額預測:2011∼2021年
  • 開發中產品:2011年
  • 摘要

第8章 Novartis的市場貢獻

  • 簡介
  • 腫瘤產品
  • 銷售額預測:2011∼2021年
  • 開發中產品:2011年
  • 摘要

第9章 SWOT分析:市場影響因素

第10章 結論

圖表

目錄

Abstract

image1

How will the market for asthma and COPD treatments perform from 2011? Our new report shows you potential drug revenues to 2021, discussing opportunities and market prospects.

Discover potential asthma and COPD drug revenues at total world, company, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.

How will competition affect the asthma and COPD treatment market? We show you how drugs such as Seretide/Advair, Singulair, Spiriva, Symbicort, Combivent and Pulmicort can perform to 2021. Receive data you need.

Find market prospects and outlooks for GSK, Merck, Boehringer Ingelheim, AstraZeneca, Novartis and Nycomed. Discover revenue forecasts.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinion from our survey. You receive 111 tables and charts and a research interview (shown in the accompanying lists).

Asthma and COPD Therapies: World Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

  • Find revenue predictions to 2021 for the world asthma and COPD drug market, seeing revenue growth
  • Discover revenue forecasts to 2021 for leading products, assessing market potentials
  • Assess leading companies, discovering their revenue prospects to 2021
  • See revenue forecasts to 2021 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India
  • Review R&D for asthma and COPD, assessing potential
  • Investigate competition and opportunities influencing the industry and market
  • See what will stimulate and restrain the industry and market from 2011
  • View opinion from our survey of the asthma and COPD field.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in asthma and COPD, helping you to stay ahead.

Order our report now to gain industry and market analysis for asthma and COPD

Our report is for everybody needing industry and market analysis for asthma and COPD treatments. Find trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Asthma & COPD Market Review
  • 1.2. Aims, Scope and Format of the Report
  • 1.3. Research and Analysis Methods

2. Introduction to Asthma & COPD Therapies

  • 2.1. Introduction
    • 2.1.1. The Asthma & COPD Market
  • 2.2. Overview of Respiratory Disorders
  • 2.3. Asthma
    • 2.3.1. Causes and Triggers of Asthma
    • 2.3.2. Increasing Prevalence
    • 2.3.3. High Economic Cost
    • 2.3.4. Treatments for Asthma
    • 2.3.5. Delivery Method - Types of Inhaler
  • 2.4. Chronic Obstructive Pulmonary Disease (COPD)
    • 2.4.1. Symptoms of COPD
    • 2.4.2. Management of COPD
    • 2.4.3. COPD on the Rise
    • 2.4.4. The Economic Burden of COPD
  • 2.5. Major Drug Classes in Treating Respiratory Diseases
    • 2.5.1. Combination Drugs
    • 2.5.2. Leukotriene Inhibitors
    • 2.5.3. Corticosteroids
    • 2.5.4. Beta-2 (Adrenoreceptor) Agonists
    • 2.5.5. Antihistamines
    • 2.5.6. Monoclonal Antibodies

3. The Asthma & COPD Therapies Market, 2011-2021

  • 3.1. The World Asthma & COPD Therapies Market in 2010
  • 3.2. Growing Market for Asthma & COPD Drug Treatments
    • 3.2.1. Sales Forecast for Asthma & COPD Therapies, 2011-2015
  • 3.3. Leading Companies in Asthma & COPD Therapies Market
    • 3.3.1. GSK Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
    • 3.3.2. GSK Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
    • 3.3.3. Merck Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
    • 3.3.4. Merck Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
    • 3.3.5. Boehringer Ingelheim Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
    • 3.3.6. Boehringer Ingelheim Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
    • 3.3.7. AstraZeneca Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
    • 3.3.8. AstraZeneca Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
    • 3.3.9. Novartis Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
    • 3.3.10. Novartis Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
    • 3.3.11. Nycomed Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
    • 3.3.12. Nycomed Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
    • 3.3.13. Summary: Leading Companies in Asthma & COPD Therapies Market, 2011-2021
  • 3.4. Asthma & COPD Therapies: Leading National Markets, 2011-2021
    • 3.4.1. The US Asthma & COPD Therapies Market, 2011-2021
    • 3.4.2. The Japanese Asthma & COPD Therapies Market, 2011-2021
    • 3.4.3. The Leading European Asthma & COPD Therapies Markets, 2011-2021
    • 3.4.4. Emerging-Economy Asthma & COPD Therapies Markets
    • 3.4.5. The Chinese Asthma & COPD Therapies Market, 2011-2021
    • 3.4.6. The Indian Asthma & COPD Therapies Market, 2011-2021
  • 3.5. Summary of Market Forecasts

4. GlaxoSmithKline' s Contribution to the Asthma & COPD Market

  • 4.1. Introduction
  • 4.2. Leading Products
  • 4.3. Sales Forecasts for Leading Products, 2011-2021
    • 4.3.1. Seretide/Advair: Sales, 2010
      • 4.3.1.1. Seretide/Advair: Sales Forecast, 2011-2015
      • 4.3.1.2. Seretide/Advair: Sales Forecast, 2016-2021
    • 4.3.2. Flixotide/Flovent
      • 4.3.2.1. Flixotide/Flovent Sales Forecast, 2011-2015
      • 4.3.2.2. Flixotide/Flovent Sales Forecast, 2016-2021
    • 4.3.3. Ventolin
      • 4.3.3.1. Ventolin Sales Forecast, 2011-2015
      • 4.3.3.2. Ventolin Sales Forecast, 2016-2021
    • 4.3.4. Serevent
      • 4.3.4.1. Serevent Sales Forecast, 2011-2015
      • 4.3.4.2. Serevent Sales Forecast, 2016-2021
    • 4.3.5. Summary: GSK Asthma & COPD Therapies: Sales, 2011-2021
  • 4.4. GSK Asthma & COPD Pipeline Products, 2011
  • 4.5. Summary: GSK Dominates Asthma & COPD Market

5. Merck' s Contribution to the Asthma & COPD Market

  • 5.1. Introduction
  • 5.2. Leading Products
  • 5.3. Sales Forecasts for Leading Products, 2011-2021
    • 5.3.1. Singulair: Sales, 2010
      • 5.3.1.1. Competitors from Other Drug Categories
      • 5.3.1.2. Singulair and Safety Concerns
      • 5.3.1.3. Singulair Patent Expiry Looms for Merck
      • 5.3.1.4. Singulair Sales Forecast, 2011-2015
      • 5.3.1.5. Singulair Sales Forecast, 2016-2021
    • 5.3.2. Proventil HFA
      • 5.3.2.1. Proventil HFA Sales Forecast, 2011-2015
      • 5.3.2.2. Proventil HFA Sales Forecast, 2016-2021
    • 5.3.3. Asmanex Twisthaler
      • 5.3.3.1. Asmanex Twisthaler: Sales Forecast, 2011-2015
      • 5.3.3.2. Asmanex Twisthaler: Sales Forecast, 2016-2021
    • 5.3.4. Summary: Merck Asthma & COPD Therapies: Sales, 2011-2021
  • 5.4. Merck Asthma & COPD Pipeline Products, 2011
  • 5.5. Summary: Merck Reliant on Singulair in Asthma & COPD Market

6. Boehringer Ingelheim' s Contribution to the Asthma & COPD Market

  • 6.1. Introduction
  • 6.2. Leading Products
  • 6.3. Sales Forecasts for Leading Products, 2011-2021
    • 6.3.1. Spiriva Demonstrates Strong Growth, 2010
      • 6.3.1.1. Safety Concerns and the UPLIFT Trial
      • 6.3.1.2. Results of the POET Study
      • 6.3.1.3. Competition and Other Restraints
      • 6.3.1.4. Spiriva: Sales Forecast, 2011-2015
      • 6.3.1.5. Spiriva: Sales Forecast, 2016-2021
    • 6.3.2. Combivent
      • 6.3.2.1. Will the Leading Position Last?
      • 6.3.2.2. Combivent Sales Forecast, 2011-2015
      • 6.3.2.3. Combivent Sales Forecast, 2016-2021
    • 6.3.3. Summary: Boehringer Ingelheim Asthma & COPD Therapies: Sales, 2011-2021
  • 6.4. Boehringer Ingelheim Asthma & COPD Pipeline Products, 2011
  • 6.5. Summary: Boehringer Ingelheim - Strong Presence in the Asthma & COPD Market

7. AstraZeneca' s Contribution to the Asthma & COPD Market

  • 7.1. Introduction
  • 7.2. Leading Products
  • 7.3. Sales Forecasts for Leading Products, 2011-2021
    • 7.3.1. Symbicort: Leading the Market, 2010
      • 7.3.1.1. Symbicort and the COPD Indication
      • 7.3.1.2. Symbicort: The SMART Concept
      • 7.3.1.3. Symbicort: Sales Forecast, 2011-2015
      • 7.3.1.4. Symbicort: Sales Forecast, 2016-2021
    • 7.3.2. Pulmicort
      • 7.3.2.1. Delivery Methods
      • 7.3.2.2. Challenges for Pulmicort: Are They Insurmountable?
      • 7.3.2.3. Pulmicort Sales Forecast, 2011-2015
      • 7.3.2.4. Pulmicort Sales Forecast, 2016-2021
    • 7.3.3. Summary: AstraZeneca Asthma & COPD Therapies: Sales, 2011-2021
  • 7.4. AstraZeneca Asthma & COPD Pipeline Products, 2011
  • 7.5. Summary: AstraZeneca Hopes to Build on Symbicort in Asthma & COPD Market

8. Novartis' Contribution to the Asthma & COPD Market

  • 8.1. Introduction
  • 8.2. Leading Products
  • 8.3. Sales Forecasts for Leading Products, 2011-2021
    • 8.3.1. Xolair Exhibits Strong Growth, 2010
      • 8.3.1.1. Xolair Sales Forecast, 2011-2015
      • 8.3.1.2. Xolair Sales Forecast, 2016-2021
    • 8.3.2. Onbrez Breezhaler
      • 8.3.2.1. US Launch Under Brand Name Arcapta Neohaler Expected in 2011
      • 8.3.2.2. Onbrez Breezhaler Sales Forecast, 2011-2015
      • 8.3.2.3. Onbrez Breezhaler Sales Forecast, 2016-2021
    • 8.3.3. Summary: Novartis Asthma & COPD Therapies: Sales, 2011-2021
  • 8.4. Novartis Asthma & COPD Pipeline Products, 2011
  • 8.5. Summary: Novartis - Growing Presence in Asthma & COPD Market

9. SWOT Analysis: Factors Influencing the Market

  • 9.1. Introduction
  • 9.2. Asthma & COPD Therapeutics: A Key Sector in Respiratory Diseases
  • 9.3. Commercial Drivers of the Asthma Therapies Market
    • 9.3.1. Expanding Patient Population
    • 9.3.2. High Economic Costs of Respiratory Diseases
    • 9.3.3. Changing Perception of COPD
    • 9.3.4. Educating the Masses: Understanding the Severity of Respiratory Disease
    • 9.3.5. Management Rather than Cure
    • 9.3.6. Lifecycle Management Strategies to Counter Patent Expiry
    • 9.3.7. Brand Awareness
    • 9.3.8. Inhalable Systems: DPI and pMDI Gain Momentum
  • 9.4. Principal Restraints for Respiratory Therapeutics
    • 9.4.1. The Threat of Generics
    • 9.4.2. Restrictions on Healthcare Budgets Favour the Use of Generics
    • 9.4.3. Purchasers Hold Increased Bargaining Power
    • 9.4.4. Maturation of the Market
  • 9.5. Research Interview: Dr Barbara Yawn, MD, Director of Research, Olmsted Medical Center, and Adjunct Professor, Department of Family and Community Health, University of Minnesota, USA
    • 9.5.1. On Key Unmet Needs
    • 9.5.2. Asthma/COPD R&D Focus in the Future
    • 9.5.3. Main Challenges Facing Asthma & COPD Research
    • 9.5.4. Advantages & Disadvantages of Current Asthma & COPD Therapies
    • 9.5.5. On Important Developments in the Sector
    • 9.5.6. On Pipeline Developments in Asthma & COPD
  • 9.6. Summary of Chapter: Market Drivers and Restraints

10. Conclusions from Our Study

  • 10.1 Introduction
  • 10.2 Leading Companies in the Market
  • 10.3 Leading Products in Asthma and COPD Market, 2010
  • 10.4 Combination Drugs Such as Seretide/Advair Continue to Dominate
  • 10.5 Addressing Unmet Needs Offers Potential for Revenue Growth
  • 10.6 Concluding Remarks

List of Tables

  • Table 2.1. Common Respiratory Diseases
  • Table 2.2. Causes of Asthma
  • Table 2.3. Asthma Triggers
  • Table 2.4. Symptoms of COPD
  • Table 3.1. Asthma & COPD Market: World Sales Forecast, 2010-2015
  • Table 3.2. Asthma & COPD Market: World Sales Forecast, 2016-2021
  • Table 3.3. GSK: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Table 3.4. GSK: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Table 3.5. Merck: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Table 3.6. Merck: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Table 3.7. Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Table 3.8. Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Table 3.9. AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Table 3.10. AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Table 3.11. Novartis: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Table 3.12. Novartis: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Table 3.13. Nycomed: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Table 3.14. Nycomed: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Table 3.15. Leading Companies: Asthma & COPD Therapies Sales Forecasts, 2010-2015
  • Table 3.16. Leading Companies: Asthma & COPD Therapies Sales Forecasts, 2016-2021
  • Table 3.17. Leading Asthma & COPD Therapies National Market Forecasts, 2010-2021
  • Table 4.1. Seretide/Advair Sales Forecast, 2010-2015
  • Table 4.2. Seretide/Advair Sales Forecast, 2016-2021
  • Table 4.3. Flixotide/Flovent Sales Forecast, 2010-2015
  • Table 4.4. Flixotide/Flovent Sales Forecast, 2016-2021
  • Table 4.5. Ventolin Sales Forecast, 2010-2015
  • Table 4.6. Ventolin Sales Forecast, 2016-2021
  • Table 4.7. Serevent Sales Forecast, 2010-2015
  • Table 4.8. Serevent Sales Forecast, 2016-2021
  • Table 4.9. GSK Asthma & COPD Sales Forecast, 2010-2015
  • Table 4.10. GSK Asthma & COPD Sales Forecast, 2016-2021
  • Table 4.11. GSK Asthma & COPD Pipeline Products, 2011
  • Table 5.1. Singulair Sales Forecast, 2010-2015
  • Table 5.2. Singulair Sales Forecast, 2016-2021
  • Table 5.3. Proventil HFA Sales Forecast, 2010-2015
  • Table 5.4. Proventil HFA Sales Forecast, 2016-2021
  • Table 5.5. Asmanex Twisthaler Sales Forecast, 2010-2015
  • Table 5.6. Asmanex Twisthaler Sales Forecast, 2016-2021
  • Table 5.7. Merck Asthma & COPD Sales Forecast, 2010-2015
  • Table 5.8. Merck Asthma & COPD Sales Forecast, 2016-2021
  • Table 5.9. Merck Asthma & COPD Pipeline Products, 2011
  • Table 6.1. Spiriva Sales Forecast, 2010-2015
  • Table 6.2. Spiriva Sales Forecast, 2016-2021
  • Table 6.3. Combivent Sales Forecast, 2010-2015
  • Table 6.4. Combivent Sales Forecast, 2016-2021
  • Table 6.5. Boehringer Ingelheim Asthma & COPD Sales Forecast, 2010-2015
  • Table 6.6. Boehringer Ingelheim Asthma & COPD Sales Forecast, 2016-2021
  • Table 7.1. Symbicort Sales Forecast, 2010-2015
  • Table 7.2. Symbicort Sales Forecast, 2016-2021
  • Table 7.3. Pulmicort Sales Forecast, 2010-2015
  • Table 7.4. Pulmicort Sales Forecast, 2016-2021
  • Table 7.5. AstraZeneca Asthma & COPD Sales Forecast, 2010-2015
  • Table 7.6. AstraZeneca Asthma & COPD Sales Forecast, 2016-2021
  • Table 8.1. Xolair Sales Forecast, 2010-2015
  • Table 8.2. Xolair Sales Forecast, 2016-2021
  • Table 8.3. Onbrez Breezhaler Sales Forecast, 2010-2015
  • Table 8.4. Onbrez Breezhaler Sales Forecast, 2016-2021
  • Table 8.5. Novartis Asthma & COPD Sales Forecast, 2010-2015
  • Table 8.6. Novartis Asthma & COPD Sales Forecast, 2016-2021
  • Table 8.7. Novartis Asthma & COPD Pipeline, 2011
  • Table 9.1. SWOT Analysis of World Asthma & COPD Therapies Market: Strengths & Weaknesses, 2011-2021
  • Table 9.2. SWOT Analysis of World Asthma & COPD Therapies Market: Opportunities & Threats, 2011-2021
  • Table 10.1. Asthma & COPD Market: World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 and 2021
  • Table 10.2. Asthma & COPD Market: Top Ten Products - Sales and Market Shares, 2010

List of Figures

  • Figure 3.1. Asthma & COPD Market: World Sales Forecast, 2010-2015
  • Figure 3.2. Asthma & COPD Market: World Sales Forecast, 2016-2021
  • Figure 3.3. GSK: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Figure 3.4. GSK: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Figure 3.5. Merck: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Figure 3.6. Merck: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Figure 3.7. Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Figure 3.8. Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Figure 3.9. AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Figure 3.10. AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Figure 3.11. Novartis: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Figure 3.12. Novartis: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Figure 3.13. Nycomed: Asthma & COPD Therapies Sales Forecast, 2010-2015
  • Figure 3.14. Nycomed: Asthma & COPD Therapies Sales Forecast, 2016-2021
  • Figure 3.15. Leading Companies: Asthma & COPD Therapies Sales Forecasts, 2010-2021
  • Figure 3.16. Leading Companies: Asthma & COPD Therapies Market Shares, 2010
  • Figure 3.17. Leading National Asthma & COPD Market Forecasts, 2010-2021
  • Figure 3.18. National Asthma & COPD Market Forecasts: Lower Range, 2010-2021
  • Figure 3.19. Asthma & COPD Therapies: Sales in Leading National Markets, 2010
  • Figure 3.20. Asthma & COPD Therapies: Sales in Leading National Markets, 2015
  • Figure 3.21. Asthma & COPD Therapies: Sales in Leading National Markets, 2018
  • Figure 3.22. Asthma & COPD Therapies: Sales in Leading National Markets, 2021
  • Figure 4.1. Seretide/Advair Sales Forecast, 2010-2021
  • Figure 4.2. Flixotide/Flovent Sales Forecast, 2010-2021
  • Figure 4.3. Ventolin Sales Forecast, 2010-2021
  • Figure 4.4. Serevent Sales Forecast, 2010-2021
  • Figure 4.5. GSK Asthma & COPD Sales Forecast, 2010-2021
  • Figure 4.6. GSK: Leading Asthma & COPD Drugs Sales Forecast, 2010-2021
  • Figure 5.1. Singulair Sales Forecast, 2010-2021
  • Figure 5.2. Proventil HFA Sales Forecast, 2010-2021
  • Figure 5.3. Asmanex Twisthaler Sales Forecast, 2010-2021
  • Figure 5.4. Merck Asthma & COPD Drugs Sales Forecast, 2010-2021
  • Figure 5.5. Merck Asthma & COPD Drugs Sales Forecast, 2010-2021
  • Figure 6.1. Spiriva Sales Forecast, 2010-2021
  • Figure 6.2. Combivent Sales Forecast, 2010-2021
  • Figure 6.3. Boehringer Ingelheim Asthma & COPD Sales Forecast, 2010-2021
  • Figure 6.4. Boehringer Ingelheim Asthma & COPD Drugs Sales Forecast, 2010-2021
  • Figure 7.1. Symbicort Sales Forecast, 2010-2021
  • Figure 7.2. Pulmicort Sales Forecast, 2010-2021
  • Figure 7.3. AstraZeneca Asthma & COPD Sales Forecast, 2010-2021
  • Figure 7.4. AstraZeneca Asthma & COPD Drugs Sales Forecast, 2010-2021
  • Figure 8.1. Xolair Sales Forecast, 2010-2021
  • Figure 8.2. Onbrez Breezhaler Sales Forecast, 2010-2021
  • Figure 8.3. Novartis Asthma & COPD Sales Forecast, 2010-2021
  • Figure 8.4. Novartis Asthma & COPD Drugs Sales Forecast, 2010-2021
  • Figure 10.1. Asthma & COPD Market: World Sales Forecast, 2010-2021
  • Figure 10.2. Asthma & COPD: Sales Forecasts for Leading Companies, 2010-2021

Companies Listed American Academy of Allergy, Asthma & Immunology

  • American Thoracic Society
  • Apotex
  • Applied Molecular Evolution
  • Arrow Group
  • Astellas
  • Asthma UK
  • AstraZeneca
  • Bayer Schering Pharma
  • Biocryst
  • Boehringer Ingelheim
  • Breath
  • British Lung Foundation
  • Centers for Disease Control and Prevention
  • Centers for Medicare and Medicaid Services
  • Chugai
  • Cipla
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Dr. Reddy' s Laboratories
  • Eli Lilly
  • European Federation of Allergy and Airways Diseases
  • European Medicines Agency (EMA)
  • European Patent Office
  • Food and Drug Administration (US FDA)
  • Genentech
  • GeoPharm
  • GlaxoSmithKline
  • Hetero Drugs
  • Johnson & Johnson
  • Kyorin
  • MedImmune
  • Merck & Co.
  • Mylan
  • National Heart, Lung and Blood Institute
  • Novartis
  • Nycomed
  • Olmsted Medical Center
  • Ono Pharmaceuticals
  • Orchid Pharmaceuticals
  • Perrigo
  • Pfizer
  • Pulmagen Therapeutics (Synergy)
  • Ranbaxy
  • Roche
  • Sandoz
  • Sanofi
  • Schering-Plough
  • Sepracor
  • Shanghai Pharmaceuticals
  • SkyePharma
  • Tanox Biosystems
  • Teva Pharmaceutical Industries
  • Theravance
  • University of Minnesota
  • US Centers for Disease Control
  • World Health Organization (WHO)
  • Wyeth (now part of Pfizer)
Back to Top